Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine Prophylaxis vs Treatment for HBV Reactivation in NHL
NCT00201318Phase 2Completed
- Sponsor
- National Health Research Institutes
- Start
- Sep 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lamivudine in hepatitis B (HBV) (2 arms), sponsored by National Health Research Institutes. Primary endpoint: Hepatitis B Reactivation. Started Sep 2001; status: completed.
02
Drugs
lamivudine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00201318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00201318.